// App-Quantinova.ai

: Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial

Researchers

Presenter

  • Danny V Jeyaraju

Principal Investigators

  • Sheida Hayati

  • Ann Polonskaia

  • Maryam Alapa

  • Manuel Ugidos

  • Andrew Browne

  • Alberto Risueno

  • Patrick Hagner

  • Vikas Gupta

  • Moshe Talpaz

  • Christopher Hernandez

  • Vincent Chia

  • Patricia Martin-Regueira

  • Daniel Lopes de Menezes

  • Ross La Motte-Mohs

  • Rajasekhar NVS Suragani

  • Anita K. Gandhi

Medical Centers

  • Translational Development and Diagnostics, Bristol Myers Squibb, Summit, NJ

  • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

  • Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ

  • Bristol Myers Squibb, Princeton

  • Bristol Myers Squibb, Cambridge, MA

  • Bristol Myers Squibb, Madrid, Spain

  • Division of Medical Oncology and Hematology, University Health Network, Toronto, Canada

Locations

  • United States

  • Spain

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • Cytokine

Drug/Treatment

  • Ruxolitinib phosphate

  • Fedratinib

Outcome

  • N/A

Study Design

  • Safety

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved